Liver Disease News and Research

RSS

The liver is one of the largest solid organs of the body. It is located in the upper right part of the abdomen. Most of the organ lies under cover of the rib cage.

Phenex commences Px-102 first-in-man Phase I study for Metabolic Syndrome and NAFLD

Phenex Pharmaceuticals AG announced today the start of a first-in-man Phase I study with its clinical drug candidate Px-102, a synthetic non-steroidal FXR agonist. The volunteers of the first dose level received the drug and showed no signs of discomfort or other adverse effects.

19 Sep 2011

Inhibitex initiates INX-189 combination Phase 2 trial in HCV-infected genotype 2/3 patients

Inhibitex, Inc., announced today that it has recently commenced dosing in a 90-patient randomized, placebo controlled, treatment guided, Phase 2 clinical trial to evaluate the safety, tolerability and antiviral activity of INX-189 in combination with pegylated interferon and ribavirin in chronic HCV-infected genotype 2 and 3 treatment naïve patients.

19 Sep 2011

Shorter treatment with telaprevir-based combination regimen may benefit hepatitis C patients

Treatment with a telaprevir-based combination regimen for hepatitis C - heretofore a chronic, destructive and difficult to manage disease - effectively can be shortened to six months in about two-thirds of patients, finds a new study published Thursday in the New England Journal of Medicine.

16 Sep 2011

NEJM publishes data from Vertex INCIVEK Phase 3 study on genotype 1 chronic hepatitis C

Vertex Pharmaceuticals Incorporated today announced that the New England Journal of Medicine (NEJM) published data from a Phase 3 study of INCIVEK (telaprevir) tablets in people with genotype 1 chronic hepatitis C who were new to treatment.

15 Sep 2011

'Achilles' heels' within HCV virus

Hopes for an effective vaccine and treatment against the potentially fatal hepatitis C virus (HCV) have received a major boost following the discovery of two 'Achilles' heels' within the virus.

14 Sep 2011

IDF, Albert Einstein College of Medicine to host Global Diabetes Symposium

While infectious diseases tend to grab media headlines and public attention, non-communicable diseases such as diabetes, cancer, cardiovascular disease, and chronic respiratory diseases together comprise the number one killer in the world and represent a serious social and economic burden to developed and developing countries alike.

14 Sep 2011

Pure maple syrup may promote a healthy liver

New research conducted at the University of Tokyo suggests that pure maple syrup may promote a healthy liver.

14 Sep 2011

Breakthrough opens new avenues for hep C vaccine

Hopes for an effective vaccine and treatment against the potentially fatal hepatitis C virus (HCV) have received a major boost following the discovery of two ‘Achilles’ heels’ within the virus.

12 Sep 2011

Specialists propose changes to allocation and distribution of organs for liver transplants

Transplantation specialists have proposed changes to the allocation and distribution of organs used for liver transplants. The recommended policy modifications take into account the scarcity of available organs, ensuring rapid allocation and delivery of the organ to those most in need in order to reduce mortality for waitlisted patients.

12 Sep 2011

Einstein led consortium to spearhead Central Africa International Epidemiologic Databases to Evaluate AIDS

In 2004, the global community acted in earnest to address the HIV/AIDS epidemic in Africa. As a result, millions of Africans are now receiving the same advanced antiretroviral therapy (ART) that has long been available in the developed world. While research shows that AIDS death rates in Africa have stabilized, little is known about the actual deployment and circumstances of treatment.

9 Sep 2011

Inhibition of Sab protein protects liver from acetaminophen toxicity

New research from the Keck School of Medicine of the University of Southern California (USC) may help prevent damage to the liver caused by drugs like acetaminophen and other stressors.

8 Sep 2011

Mesoblast receives EMA clearance to initiate Revascor Phase 2 trial for heart attacks

Global regenerative medicine company, Mesoblast Limited, today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor(TM) in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack.

5 Sep 2011

Einstein researchers develop tuberculosis vaccine candidate

Researchers at Albert Einstein College of Medicine of Yeshiva University report in the September 4 online edition of Nature Medicine that they have developed a tuberculosis (TB) vaccine candidate that proved both potent and safe in animal studies.

5 Sep 2011

Mayo Clinic and IC-MedTech enter collaborative research agreement with Summa Health System

Researchers from the Mayo Clinic and representatives from IC-MedTech signed a collaborative research agreement with Summa Health System to study the usage of Apatone, a proprietary combination of Vitamin-C and Vitamin-K3.

2 Sep 2011

Aerobic exercise best for belly fat reduction: Study

A new study has shown that the best type of exercise to burn unhealthy belly fat is aerobic exercise. The results showed that people who did aerobics for eight months lost about 2.5 square inches of belly fat, as measured on a CT scan. That's about 1.5 times as much as people who did a combination of aerobic exercise and weight lifting, and about 20 times as much as those who only lifted weights.

31 Aug 2011

Medivir completes enrollment of three TMC435 phase 3 trials on CHC genotype-1 infection

MedivirAB is an emerging researchbased specialty pharmaceutical company focused on infectious diseases. Medivir today announced that its investigational protease inhibitor TMC435, developed by Tibotec Pharmaceuticals, has successfully completed enrollment of three ongoing global phase 3 trials and further reports that all patients are now on TMC435 or active control treatment.

31 Aug 2011

Liver Disease News and Research

Further Reading

Phenex commences Px-102 first-in-man Phase I study for Metabolic Syndrome and NAFLD

Inhibitex initiates INX-189 combination Phase 2 trial in HCV-infected genotype 2/3 patients

Shorter treatment with telaprevir-based combination regimen may benefit hepatitis C patients

NEJM publishes data from Vertex INCIVEK Phase 3 study on genotype 1 chronic hepatitis C

'Achilles' heels' within HCV virus

IDF, Albert Einstein College of Medicine to host Global Diabetes Symposium

Pure maple syrup may promote a healthy liver

Breakthrough opens new avenues for hep C vaccine

Specialists propose changes to allocation and distribution of organs for liver transplants

Einstein led consortium to spearhead Central Africa International Epidemiologic Databases to Evaluate AIDS

Inhibition of Sab protein protects liver from acetaminophen toxicity

Mesoblast receives EMA clearance to initiate Revascor Phase 2 trial for heart attacks

Einstein researchers develop tuberculosis vaccine candidate

Mayo Clinic and IC-MedTech enter collaborative research agreement with Summa Health System

Aerobic exercise best for belly fat reduction: Study

Medivir completes enrollment of three TMC435 phase 3 trials on CHC genotype-1 infection

U-M offers transplantation for patients with bile duct cancer

Colchicine more effective than placebo for recurrent pericarditis

Study: Aerobic training effectively reduces belly fat

Alcohol related hospital admissions rise in Britain

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News